Symbiotec Pharmalab Limited has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India to raise up to ₹2,180 crore through an initial public offering.
The proposed IPO comprises a fresh issue of equity shares worth ₹150 crore and an offer for sale of up to ₹2,030 crore by selling shareholders. The equity shares, with a face value of ₹2 each, are proposed to be listed on the BSE and the NSE.
According to the DRHP, the company intends to utilise the net proceeds from the fresh issue towards prepayment or repayment of certain outstanding borrowings and for general corporate purposes.
Symbiotec Pharmalab is a research and development–driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. As per the F&S Report cited in the DRHP, the company held a global volume market share of 36.2% in corticosteroid APIs and 44.2% in steroidal-hormone APIs in FY25and is the only company globally to have a presence across the top 10 corticosteroid and steroidal-hormone APIs.
JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited are the book-running lead managers to the issue.
Comments are closed.